In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Medicare Part B vs. Part D

Executive Summary

Drug companies are struggling with which reimbursement strategy to pursue. It

Related Content

Medicare Rebates: Bigger is Better, But is Big Government Best?
The Threat of Reconciliation: Remembering the Part D Vote
Payers and Partnerships: The Top Three Reimbursement Questions for Biotech Companies
iDoc: E-Prescribing Gains Momentum, But Roadblocks Remain
Living in a Bipolar World: Implications of the EPO Safety Debate (Part 1)
The Other Agency: CMS Shocks Wall Street-and Amgen Takes a Hit
Bad Blood: The Amgen/J&J Feud Takes a Perilous Turn
The End of Buy-and-Bill?
The Real Test for Gardasil: Money, not Morals
Show Me the Value


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts